Key result
This review outlines the risk factors, mechanisms, and an algorithm for diagnosing heart failure with preserved ejection fraction in patients with tricuspid regurgitation.
Provides an algorithm for applying validated diagnostic criteria for HFpEF in patients with tricuspid regurgitation, highlighting it as an underdiagnosed and undertreated condition.
An illustration of the risk factors, clinical features, possible mechanisms, and management of tricuspid regurgitation and heart failure with preserved ejection fraction (A–C). An algorithm outlining the application of validated diagnostic criteria of heart failure with preserved ejection fraction amongst patients with tricuspid regurgitation (D). ACC/AHA/HFSA, American College of Cardiology/American Heart Association/Heart Failure Society of America; BMI, body mass index; ESC-HFA, European Society of Cardiology - Heart Failure Association; GLP-1, glucagon-like peptide 1; HFpEF, heart failure with preserved ejection fraction; LV, left ventricle; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; PASP, pulmonary artery systolic pressure; PVD, pulmonary vascular disease; RA, right atrium; RV, right ventricle; SGLT-2, sodium-glucose cotransporter-2; TEER, transcatheter edge-to-edge repair; TR, tricuspid regurgitation; TTVR: transcatheter tricuspid valve replacement.
No takes yet. Share an insight, caveat, or question.
Talha et al. (2024) conducted a review in Tricuspid regurgitation and heart failure with preserved ejection fraction. This review outlines the risk factors, mechanisms, and an algorithm for diagnosing heart failure with preserved ejection fraction in patients with tricuspid regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: